Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Cardiovascular toxicity is a potential short-or long-term complication of anticancer therapy.
Exposure to chemotherapy medications, primarily the anthracycline class, can lead to …

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

Cardiotoxicity is a common complication of many anti-cancer agents and it remains a major
limitation, strongly impacting the quality of life and the overall survival, regardless of the …

Modern treatment strategies have led to improvements in cancer survival, however, these
gains might be offset by the potential negative effect of cancer therapy on cardiovascular …

Cardiotoxicity due to cancer treatment is of rising concern, for both cardiologists and
oncologists, because it may have a significant impact on cancer patient management and …

Cardiovascular (CV) toxicity is a potential short-or long-term complication of various
anticancer therapies. Some drugs, such as anthracyclines or other biological agents, have …

This position statement from the Heart Failure Association of the European Society of
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …